Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.
You may also be interested in...
Merck KGaA Turns To Outsider Oschmann To Head Pharma Unit
Merck & Co.'s emerging markets head Stefan Oschmann will succeed Merck KGaA's Elmar Schnee as head of pharmaceuticals effective Jan. 1.
Merck KGaA Turns To Outsider Oschmann To Head Pharma Unit
Merck & Co.'s emerging markets head Stefan Oschmann will succeed Merck KGaA's Elmar Schnee as head of pharmaceuticals effective Jan. 1.
EU Regulators Reject Merck KGaA's Oral MS Drug Cladribine
Surprise rejection hits German drugmaker hard and casts doubt over FDA approval.